Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients

Colin Pawlowski, AJ Venkatakrishnan, Christian Kirkup, Gabriela Berner, Arjun Puranik, John C. O’Horo, Andrew D. Badley, Venky Soundararajan
doi: https://doi.org/10.1101/2020.10.06.20208025

Article Information

doi 
https://doi.org/10.1101/2020.10.06.20208025
History 
  • October 11, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Colin Pawlowski1,+,
  2. AJ Venkatakrishnan1,+,
  3. Christian Kirkup1,+,
  4. Gabriela Berner1,
  5. Arjun Puranik1,
  6. John C. O’Horo2,
  7. Andrew D. Badley2 and
  8. Venky Soundararajan1,*
  1. 1nference, inc., One Main Street, Suite 400, East Arcade, Cambridge, MA 02142, USA
  2. 2Mayo Clinic, Rochester MN, USA
  1. ↵*Address correspondence to VS (venky{at}nference.net)

  1. ↵+ Equal contribution

Back to top
Posted October 11, 2020.
Download PDF
Data/Code
Email
Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients
Colin Pawlowski, AJ Venkatakrishnan, Christian Kirkup, Gabriela Berner, Arjun Puranik, John C. O’Horo, Andrew D. Badley, Venky Soundararajan
medRxiv 2020.10.06.20208025; doi: https://doi.org/10.1101/2020.10.06.20208025
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area